A study on the use of TK1 to monitor prostate cancer has been accepted for poster presentation at the AACR annual meeting 2020

A study by Professor Teemu Murtola of Tampere University Hospital, Finland, on the use of Thymidine Kinase 1 as a marker for the risk of prostate cancer progression following diagnosis has now been accepted for poster presentation on the American Association of Cancer Research 2020 (AACR 2020) held in San Diego, California, USA.

The poster is entitled “Serum Thymidine Kinase 1 levels predict prostate cancer-specific survival” and is based on a study by Teemu Murtola of Tampere University Hospital. In the study the samples from two groups of men were used; one with localized prostate cancer and another with metastatic disease at diagnosis. Serum Thymidine kinase 1 (TK1) protein levels at the time of diagnosis were measured with AroCell TK210 ELISA and compared with the extent and speed of disease progression over a period of 10 years.

The abstract of the study will be published online on the AACR website on Tuesday, March 24, 2020, and the poster will be presented on Monday, April 27.